# Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia

> **NCT01923116** · PHASE1,PHASE2 · COMPLETED · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 40 (actual)

## Conditions studied

- Anal Intraepithelial Neoplasia
- HIV

## Interventions

- **DRUG:** HPV-16 vaccine

## Key facts

- **NCT ID:** NCT01923116
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2017-06
- **Final completion:** 2017-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-03-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01923116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01923116, "Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01923116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*